The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) could affect COVID-19 outcomes by modulating the immune response, which, in turn, might favor viral replication and/or confer protection from COVID-19 induced inflammatory response CASE REPORT: We report on two MS patients treated with cladribine, with heterogeneous demographics and clinical features, who developed mild or no symptoms from COVID-19 and produced anti-SARS-CoV-2 antibodies, notwithstanding low lymphocyte levels.

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice / De Angelis, Marcello; Petracca, Maria; Lanzillo, Roberta; Brescia Morra, Vincenzo; Moccia, Marcello. - In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. - ISSN 2211-0348. - 45:(2020), p. 102452. [10.1016/j.msard.2020.102452]

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice

Petracca, Maria
Secondo
;
2020

Abstract

The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) could affect COVID-19 outcomes by modulating the immune response, which, in turn, might favor viral replication and/or confer protection from COVID-19 induced inflammatory response CASE REPORT: We report on two MS patients treated with cladribine, with heterogeneous demographics and clinical features, who developed mild or no symptoms from COVID-19 and produced anti-SARS-CoV-2 antibodies, notwithstanding low lymphocyte levels.
2020
COVID-19; cladribine; lymphocytes; multiple sclerosis
01 Pubblicazione su rivista::01i Case report
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice / De Angelis, Marcello; Petracca, Maria; Lanzillo, Roberta; Brescia Morra, Vincenzo; Moccia, Marcello. - In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. - ISSN 2211-0348. - 45:(2020), p. 102452. [10.1016/j.msard.2020.102452]
File allegati a questo prodotto
File Dimensione Formato  
De Angelis_Mild or no COVID-19 symptoms_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 425.19 kB
Formato Adobe PDF
425.19 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1544631
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 32
social impact